Northwest Biotherapeutics Inc., of Bethesda, Md., said the data safety monitoring board has made an unblinded review of the safety data for the company’s ongoing international phase III glioblastoma trial with DCVax-L, using activated dendritic cells, and has recommended that the trial continue as planned.